Gossamer Bio, Inc. Common Stock (GOSS) Stock
Key stats
- Market cap
- $71.50M
- Price / Earnings ratio
- -0.6x
- EPS (TTM)
- -$45.60
- Volume
- Loading
- 52-week high
- $12.52
- 52-week low
- $0.11
Source: third-party data provider, as of November 13, 2026
Compare with GOSS
Recent news

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
GOSS

Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
GOSS

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
GOSS

Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio Announces 1-for-80 Reverse Stock Split
GOSS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 61.11
- MACD 12/26/9
- 0.09
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.28
- SMA 50
- $10.67
- Price above SMA 50
- EMA 50
- $10.98
- Price above EMA 50
- SMA 200
- $33.11
- Price below SMA 200
- EMA 200
- $59.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
GOSS

Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
GOSS

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
GOSS

Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio Announces 1-for-80 Reverse Stock Split
GOSS

Gossamer Bio to Present at Cantor Global Healthcare Conference
Gossamer Bio to Present at Cantor Global Healthcare Conference
GOSS

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
GOSS

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
GOSS

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
GOSS

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
GOSS

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
GOSS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Gossamer Bio, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Faheem Hasnain | Co-Founder, CEO, President & Chairman | 1958 |
| Mr. Bryan Giraudo | COO & CFO | 1975 |
| Mr. Robert Paul Smith Jr. | Chief Commercial Officer | 1969 |
| Mr. Christian Waage J.D. | Executive VP, General Counsel & Secretary | 1967 |
| Ms. Jeanine Anthony | Senior Vice President of Marketing | — |
| Ms. Deanna Weber | Executive Vice President of Human Resources | — |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | 1966 |
| Ms. Caryn L. Peterson | Chief Development Officer | 1959 |
| Kelly Dawson | Senior Vice President & Program Team Lead | — |
| Mr. Conor O'Donovan | Senior Vice President of Regulatory Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 61.11
- MACD 12/26/9
- 0.09
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.28
- SMA 50
- $10.67
- Price above SMA 50
- EMA 50
- $10.98
- Price above EMA 50
- SMA 200
- $33.11
- Price below SMA 200
- EMA 200
- $59.85
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $32.00
- Average
- $94.50
- High
- $160.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.0 | +4.7 | ||||||||||
| 2022 | -19.3 | -4.9 | -4.3 | -23.2 | -1.3 | +21.0 | +34.3 | +24.9 | -17.8 | -4.8 | -21.1 | -73.7 |
| 2023 | +29.4 | -38.9 | -24.1 | +15.2 | +1.5 | -2.4 | +2.3 | -25.2 | -21.0 | -35.1 | +62.5 | +7.1 |
| 2024 | -13.4 | +69.9 | -14.5 | -44.1 | -16.9 | +55.2 | -5.3 | +0.0 | +13.8 | -16.2 | -19.5 | +23.3 |
| 2025 | +2.1 | +19.4 | -6.8 | +3.0 | +4.7 | +6.0 | +63.2 | +23.5 | +1.5 | -1.6 | +39.7 | -1.3 |
| 2026 | -20.8 | -83.1 | -23.3 | +0.0 | -37.8 | -20.0 | +0.0 | +0.0 | +6870.6 | -5.0 | +19.4 |
Corporate actions
Upcoming
No upcoming corporate actions for GOSS



